Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7–33. SiegelRL MillerKD FuchsHE JemalA Cancer statistics, 2022 CA Cancer J Clin. 2022 72 7 33 Search in Google Scholar

[2] Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016; 25:16–27. TorreLA SiegelRL WardEM JemalA Global cancer incidence and mortality rates and trends – an update Cancer Epidemiol Biomarkers Prev. 2016 25 16 27 Search in Google Scholar

[3] Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018; 37:1–15. TangL WeiF WuY HeY ShiL XiongF Role of metabolism in cancer cell radioresistance and radiosensitization methods J Exp Clin Cancer Res. 2018 37 1 15 Search in Google Scholar

[4] Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer/Radiothér. 2014; 18:391–5. RekersNH TroostEG ZegersCM GermeraadWT DuboisLJ LambinP Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives Cancer/Radiothér. 2014 18 391 5 Search in Google Scholar

[5] Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018; 17:1–11. ZhongY DuY YangX MoY FanC XiongF Circular RNAs function as ceRNAs to regulate and control human cancer progression Mol Cancer. 2018 17 1 11 Search in Google Scholar

[6] Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001; 11:328–337. JonesHA HahnSM BernhardE McKennaWG Ras inhibitors and radiation therapy Semin Radiat Oncol. 2001 11 328 337 Search in Google Scholar

[7] Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol. 2006; 16:59–64. ChinnaiyanP AllenGW HarariPM Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras Semin Radiat Oncol. 2006 16 59 64 Search in Google Scholar

[8] Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010; 3:1–11. FréminC MelocheS From basic research to clinical development of MEK1/2 inhibitors for cancer therapy J Hematol Oncol. 2010 3 1 11 Search in Google Scholar

[9] Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007; 1773:1213–26. ShaulYD SegerR The MEK/ERK cascade: from signaling specificity to diverse functions Biochim Biophys Acta. 2007 1773 1213 26 Search in Google Scholar

[10] Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009; 15:3050–7. ChungEJ BrownAP AsanoH MandlerM BurganWE CarterD In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase Clin Cancer Res. 2009 15 3050 7 Search in Google Scholar

[11] Xia Y, Wang Y, Xue L, Yu D. Radiosensitizing effect of MEK specific inhibitor U0126 on A549 cells and its mechanism. J Radiat Res Radiat Proc. 2014; 32:10–5. XiaY WangY XueL YuD Radiosensitizing effect of MEK specific inhibitor U0126 on A549 cells and its mechanism J Radiat Res Radiat Proc. 2014 32 10 5 Search in Google Scholar

[12] Estrada-Bernal A, Chatterjee M, Haque SJ, Yang L, Morgan MA, Kotian S, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015; 14:3713–24. Estrada-BernalA ChatterjeeM HaqueSJ YangL MorganMA KotianS MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways Cell Cycle. 2015 14 3713 24 Search in Google Scholar

[13] Zhu Z, Tian H. Radiosensitizing effects of novel benzothiadiazole derivatives on KRAS-mutant non-small cell lung cancers. Int J Biomed Eng. 2018; 41:138–47. ZhuZ TianH Radiosensitizing effects of novel benzothiadiazole derivatives on KRAS-mutant non-small cell lung cancers Int J Biomed Eng. 2018 41 138 47 Search in Google Scholar

[14] Cheng Y, Wang X, Xia X, Zhang W, Tian H. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer. Int J Cancer. 2019; 145:586–96. ChengY WangX XiaX ZhangW TianH A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer Int J Cancer. 2019 145 586 96 Search in Google Scholar

[15] Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, et al. Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. 2017; 18:367. LiuG PeiF YangF LiL AminAD LiuS Role of autophagy and apoptosis in non-small-cell lung cancer Int J Mol Sci. 2017 18 367 Search in Google Scholar

[16] Neal RD, Hamilton W, Rogers TK. Lung cancer. BMJ. 2014; 349:g6560. doi: 10.1136/bmj.g6560 NealRD HamiltonW RogersTK Lung cancer BMJ. 2014 349 g6560 10.1136/bmj.g6560 Open DOISearch in Google Scholar

[17] Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao M-S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006; 8:30–8. Aviel-RonenS BlackhallFH ShepherdFA TsaoM-S K-ras mutations in non-small-cell lung carcinoma: a review Clin Lung Cancer. 2006 8 30 8 Search in Google Scholar

[18] Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non–small-cell lung cancer. J Clin Oncol. 1999; 17:668–75. GrazianoSL GambleGP NewmanNB AbbottLZ RooneyM MookherjeeS Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non–small-cell lung cancer J Clin Oncol. 1999 17 668 75 Search in Google Scholar

[19] Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Inv Drug. 2018; 27:17–30. KimC GiacconeG MEK inhibitors under development for treatment of non-small-cell lung cancer Expert Opin Inv Drug. 2018 27 17 30 Search in Google Scholar

[20] Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, et al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat Commun. 2019; 10:1–16. JonesGG Del RíoIB SariS SekerimA YoungLC HartigN SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers Nat Commun. 2019 10 1 16 Search in Google Scholar

[21] Lu L, Jiang M, Zhu C, He J, Fan S. Amelioration of whole abdominal irradiation-induced intestinal injury in mice with 3, 3′-Diindolylmethane (DIM). Free Radical Biol Med. 2019; 130:244–55. LuL JiangM ZhuC HeJ FanS Amelioration of whole abdominal irradiation-induced intestinal injury in mice with 3, 3′-Diindolylmethane (DIM) Free Radical Biol Med. 2019 130 244 55 Search in Google Scholar